Topics
News
CME/CE
Editorial Advisory Board
Partners
Subscribe
- General Dermatology
- Eczema
- Alopecia
- Aesthetics
- Vitiligo
- COVID-19
- Actinic Keratosis
- Precision Medicine and Biologics
- Rare Disease
- Wound Care
- Rosacea
- Psoriasis
- Psoriatic Arthritis
- Atopic Dermatitis
- Melasma
- NP and PA
- Skin Cancer
- Hidradenitis Suppurativa
- Drug Watch
- Pigmentary Disorders
- Acne
- Pediatric Dermatology
- Practice Management
Experts Present Background on Long-Term Safety Study of Upadacitinib for AD
Christopher Bunick, MD, PhD, introduces an integrated analysis of phase three studies analyzing the long-term safety of upadacitinib as treatment for atopic dermatitis (AD). He also highlights a burgeoning standard to assess the safety of treatment.
EP: 1.JAK Inhibitor Overview and Relevance to AD
EP: 2.Comparing Current Treatment Agents for AD
EP: 3.Clinical Experience With JAK Inhibitor in AD
Now Viewing
EP: 4.Experts Present Background on Long-Term Safety Study of Upadacitinib for AD
EP: 5.Experts on Results of Long-Term Safety Study of Upadacitinib for AD
EP: 6.Conclusions of Study on Long-Term Safety Study of Upadacitinib for AD
EP: 7.Assessing Risk Factors of Oral JAK Inhibitors and Traditional Agents
EP: 8.Experts Present Background on JAK Inhibitor vs Systemic Immunosuppressant Safety Study
EP: 9.Experts on Results of JAK Inhibitor vs Systemic Immunosuppressant Safety Study
EP: 10.Visualizing Safety Rates: Drug Events, Disease Baseline, and General Population Baseline
EP: 11.Box Warning and JAK Inhibitor
EP: 12.JAK Inhibitor Selectivity
EP: 13.Conclusions of JAK Inhibitor vs Systemic Immunosuppressant Safety Study
EP: 14.Evolving the Standard of Care for AD: Safety and Treatment Response
EP: 15.Transitioning Patients from Traditional Immunosuppressive Agents to JAK Inhibitor
EP: 16.AD Endotypes and Outcomes
EP: 17.Final Thoughts on JAK Inhibitor for AD
Recent Videos
Related Content
